Nuvalent Surges 39% Premarket. GSK Acquires for $10.6 Billion at 40% Premium, New CEO’s First Big Bet on Lung Cancer Field

TradingKey - British pharmaceutical giant GSK announced on June 9 that it will acquire U.S. biotechnology company Nuvalent (NUVL) for $10.6 billion in an all-cash deal to bolster its lung cancer drug pipeline. This transaction marks GSK's largest acquisition in over a decade and represents the first major strategic move under new CEO Luke Miels.